Interaction risk simulator across three medication classes
A stabilized patient weighs cannabis use against their prescribed regimen.
Cannabis is common among psychiatric patients; effects vary widely by drug class.
THC drives psychoactive and sedative effects; CBD drives enzyme inhibition effects.
Toggle medication class and THC potency to see risk pathways shift live.
Cannabis compounds with sedatives, amplifying drowsiness and impairment.
THC and benzodiazepines both dampen CNS activity, compounding sedation risk.
Higher THC potency increases sedative load layered onto medication effects.
Impaired coordination, drowsiness, and respiratory risk rise with co-use.
High-potency THC can worsen symptoms in antipsychotic-treated patients.
THC potency interacts sharply with antipsychotic-treated psychotic disorders.
Low-THC products carry much lower relapse risk than high-potency ones.
Antipsychotic class plus high THC together produce the sharpest risk spike.
CBD inhibits CYP450 enzymes, raising blood levels of some medications.
CBD slows CYP450 enzymes that normally clear certain medications.
Antidepressants and antipsychotics metabolized via these pathways see level rises.
Elevated blood levels can increase side effects without a dose change.
Class and diagnosis both matter; psychotic-disorder patients face the most concern.
Sedation, psychosis, and pharmacokinetic risk behave independently by class.
Patients with psychotic disorders face the most significant specific concern.
Assess cannabis risk per medication class and underlying diagnosis together.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Benzodiazepine | Sedative combination | Additive CNS depression with THC | Highest sedation risk |
| Antipsychotic | Psychotic disorders | High-THC potency worsens symptoms/relapse | Highest psychosis risk |
| Antidepressant | CYP450-metabolized agents | CBD inhibition raises blood levels | Highest PK-elevation risk |